Click here to go to S-1 with Anomalous Portions Highlighted

Read Articles from the Web about the Company Sorted by Complexity

Dexmethylphenidate controlled release - AdisInsight - Springer

https://adisinsight.springer.com/drugs/800048266
Dexmethylphenidate controlled release - Cingulate Therapeutics ... application to US FDA (Cingulate Therapeutics, pipeline, March 2020) Updated 17 Mar 2020.

CTx-1301 Comparative Bioavailability Study - Full Text View

https://clinicaltrials.gov/ct2/show/NCT04138498
Oct 24, 2019 — Cingulate Therapeutics. Information provided by (Responsible Party):. Cingulate Therapeutics. Study Details; Tabular View · Study Results ...

Cingulate Therapeutics & Catalent Sign Exclusive ADHD

https://drug-dev.com/cingulate-therapeutics-catalent-sign-exclusive-adhd-agreement/
Cingulate Therapeutics primary focus is to develop and commercialize the CTx ... in ADHD,” added Shane Schaffer, Chairman and CEO of Cingulate Therapeutics.

Cingulate Therapeutics LLC - Relationship Science

https://relationshipscience.com/organization/cingulate-therapeutics-llc-227715863
View Cingulate Therapeutics LLC, including Executives & Employees and Board of ... Chairman & Chief Executive Officer at Cingulate Therapeutics LLC.

Cingulate Therapeutics Information - RocketReach

https://rocketreach.co/cingulate-therapeutics-profile_b5f782ccf42eb520
Cingulate Therapeutics Revenue: $2.00 Million | Employees: 16 | Industry: ... Who is the Chairman and Chief Executive Officer of Cingulate Therapeutics?

Neurobiology Companies and Organizations - Biotech ...

https://www.biotech-careers.org/company-core-activity/neurobiology
Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric . ... Cingulate Therapeutics. Business Area(s):. Neurobiology. Description:.

2021 Attention Deficit Hyperactivity Disorder (ADHD) Drugs In ...

https://www.businesswire.com/news/home/20210817005460/en/2021-Attention-Deficit-Hyperactivity-Disorder-ADHD-Drugs-In-Development---ResearchAndMarkets.com
Aug 17, 2021 — The pipeline guide reviews pipeline therapeutics for Attention Deficit ... Cennerv Pharma (S) Pte Ltd; Cingulate Therapeutics LLC ...

Catalent and Cingulate Therapeutics Sign Exclusive Agreement

https://www.catalent.com/catalent-news/catalent-and-cingulate-therapeutics-sign-exclusive-agreement-for-development-of-new-adhd-treatments/
Sep 24, 2014 — Cingulate Therapeutics (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of ...

Cingulate Therapeutics Headquarter Location - CB Insights

https://www.cbinsights.com/company/cingulate-therapeutics
Cingulate Therapeutics (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of products for the treatment of ...

Cingulate Therapeutics | EquityNet

https://www.equitynet.com/c/cingulate-therapeutics251
CINGULATE THERAPEUTICS (CTx) is a privately held, pharmaceutical company, headquartered in Morristown, NJ. At present, CTx is developing TWO (2) assets for ...

ADHD drug developer Cingulate files for a $58 million IPO

https://www.firstwordpharma.com/node/1862516?tsid=28&region_id=3
4 days ago — The firm is using its proprietary Precision Timed Release (PTR) drug delivery platform technology to advance a pipeline of next-generation ...

The Value of CTx-1301 for ADHD - HCPLive

https://www.hcplive.com/view/brams-multidose-adhd-pill
Jan 18, 2021 — In an interview with HCPLive®, Matthew Brams, MD, Chief Medical Officer of Cingulate Therapeutics, and Shane Schaffer, PharmD, ...

View PDF Plus - Mary Ann Liebert, Inc.

https://www.liebertpub.com/doi/pdfplus/10.1089/cap.2019.0070
by AC Childress · 2020 · Cited by 6 — (ADHD) seek treatment primarily due to functional impair- ment (e.g., strained relations, ... Labs, Arbor Pharmaceuticals, Cingulate Therapeutics, Ironshore.

Cingulate Therapeutics Presents Results of Pivotal Phase 2 ...

https://www.prnewswire.com/news-releases/cingulate-therapeutics-presents-results-of-pivotal-phase-2-clinical-trial-for-lead-adhd-candidate-ctx-1301-at-the-american-association-of-child-and-adolescent-psychiatry-annual-meeting-301159257.html
Oct 26, 2020 — Cingulate's two lead assets in the $18B ADHD market include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) –both first-line ...

Cingulate Therapeutics names new chief operating officer.

https://www.thefreelibrary.com/Cingulate+Therapeutics+names+new+chief+operating+officer-a0533097511
Laurie's experience in all aspects of branded pharmaceutical life cycle management from clinical drug development through commercialisation is a major asset, ...